Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keisuke Shirai

Showing results (1-10 of 81) with videos related to

Pageof 9
Sort By:
BMJ Case Reports|September 24, 2016
Safety and efficacy of pembrolizumab in a patient with advanced melanoma on haemodialysisRubens Chang, Keisuke Shirai
American Journal of Clinical Oncology|February 8, 2011
Systemic therapy for squamous cell carcinoma of the skin in organ transplant recipientsJames Leroy Wells, Keisuke Shirai
Current Treatment Options in Oncology|October 27, 2007
Molecular targets in squamous cell carcinoma of the head and neckKeisuke Shirai, Paul E O'Brien
Thescientificworldjournal|July 11, 2007
Use of low molecular weight heparin and aminocaproic acid in chronic DIC associated with prostate cancer--a case reportKeisuke Shirai, Uzair B Chaudhary
Melanoma Research|May 12, 2018
Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care centerMuhammad Z Afzal, Keisuke Shirai
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 2, 2019
Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With PembrolizumabMuhammad Z Afzal, Keisuke Shirai
Advances in Experimental Medicine and Biology|December 16, 2015
Anaplastic Lymphoma Kinase (ALK) Signaling in Lung CancerSai-Hong Ignatius Ou, Keisuke Shirai
Transplant Immunology|September 21, 2023
Durable complete response to early immunotherapy discontinuation in a kidney transplant recipient with advanced cutaneous squamous cell carcinoma: A case report and review of literatureZiyao Lu, Muhammad Afzal, Keisuke Shirai
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 31, 2019
Prognostic Significance of Hematological Indices in Malignant Melanoma Treated With Immune Checkpoint InhibitorsMuhammad Z Afzal, Tayyaba Sarwar, Keisuke Shirai
Journal of Thoracic Disease|August 3, 2018
A tertiary care cancer center experience with carboplatin and pemetrexed in combination with pembrolizumab in comparison with carboplatin and pemetrexed alone in non-squamous non-small cell lung cancerMuhammad Zubair Afzal, Konstantin Dragnev, Keisuke Shirai
Pageof 9

Showing results (1-10 of 81) with videos related to

Sort By:
Pageof 9
BMJ Case Reports|September 24, 2016
Safety and efficacy of pembrolizumab in a patient with advanced melanoma on haemodialysisRubens Chang, Keisuke Shirai
American Journal of Clinical Oncology|February 8, 2011
Systemic therapy for squamous cell carcinoma of the skin in organ transplant recipientsJames Leroy Wells, Keisuke Shirai
Current Treatment Options in Oncology|October 27, 2007
Molecular targets in squamous cell carcinoma of the head and neckKeisuke Shirai, Paul E O'Brien
Thescientificworldjournal|July 11, 2007
Use of low molecular weight heparin and aminocaproic acid in chronic DIC associated with prostate cancer--a case reportKeisuke Shirai, Uzair B Chaudhary
Melanoma Research|May 12, 2018
Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care centerMuhammad Z Afzal, Keisuke Shirai
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 2, 2019
Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With PembrolizumabMuhammad Z Afzal, Keisuke Shirai
Advances in Experimental Medicine and Biology|December 16, 2015
Anaplastic Lymphoma Kinase (ALK) Signaling in Lung CancerSai-Hong Ignatius Ou, Keisuke Shirai
Transplant Immunology|September 21, 2023
Durable complete response to early immunotherapy discontinuation in a kidney transplant recipient with advanced cutaneous squamous cell carcinoma: A case report and review of literatureZiyao Lu, Muhammad Afzal, Keisuke Shirai
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 31, 2019
Prognostic Significance of Hematological Indices in Malignant Melanoma Treated With Immune Checkpoint InhibitorsMuhammad Z Afzal, Tayyaba Sarwar, Keisuke Shirai
Journal of Thoracic Disease|August 3, 2018
A tertiary care cancer center experience with carboplatin and pemetrexed in combination with pembrolizumab in comparison with carboplatin and pemetrexed alone in non-squamous non-small cell lung cancerMuhammad Zubair Afzal, Konstantin Dragnev, Keisuke Shirai
Pageof 9